CMND up 16.4% on Sep 8 2026 with no filing that explains it
CMND+16.4%on Tue Sep 8 2026
Clearmind Medicine Inc. Common Shares was up 16.4% on the day at $1.35, ranked #1 on 580× its usual five-minute volume, when TapeRank recorded this unexplained move at 07:45 ET during the pre-market session.
THE DAY ON THE LIST · 1 EVENT
- 07:45 ETUNEXPLAINED MOVE · PRE-MARKET
$1.35 · ▲ 16.4% ON THE DAY · 580× 5M RVOL · RANK #1
UNEXPLAINEDCONFIDENCE3/5CMND is essentially flat pre-market despite a 67.5x surge in relative volume, even as the company disclosed Yale IRB approval enabling patient recruitment for its Phase I/II trial. The elevated volume with negligible price movement points to positioning or order flow rather than a price reaction to the news itself.
WHYA clinical trial regulatory milestone would typically be expected to move a micro-float stock meaningfully, but the price is up only 0.3% despite outsized volume, so the news and the move are mismatched in the opposite direction of a typical stretched case.ANALYZED 07:43 ET · 1 MIN AGO · ANTHROPIC/CLAUDE-SONNET-5THE ROW AND SESSION LEVELS AT 07:45 ET
LAST1.35DAY▲ 16.4%5 MIN▲ 16.39%5M RVOL580×5M $VOL$336KFLOAT*1.0MRANK#1SESSIONPRE-MARKETVWAP1.22HOD1.33LOD1.11OR HIGH—OR LOW—PREV CLOSE1.16PM HIGH1.33PM LOW1.11GAP▲ 11.21% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
THE SESSION
- 09:30 ETOpened at $1.15, -0.9% on the previous close of $1.16
- 09:30 ETRegular-session high, $1.15
- 09:37 ETRegular-session low, $0.9199
- 15:59 ETLast trade of the regular session, $1.04, -10.3% on the previous close of $1.16
- Volume: 833K shares in regular hours, 1.5M before the open
CMND opened at $1.15 after TapeRank recorded an unexplained premarket move at $1.35, with 1.5M shares traded before the open. It slipped to a session low of $0.9199 by 09:37 ET and recovered to finish at $1.04, down 10.3% from the previous close, with no halts. TapeRank’s read tied the activity to the company’s disclosure that Yale’s IRB had approved patient recruitment for its Phase I/II trial, but marked the move unexplained because the elevated volume was not matched by a meaningful price reaction.
WRITTEN THU OCT 15 2026 19:22 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS · 24H BEFORE THE MOVE
- 03:43 ET6-K — REPORT OF FOREIGN PRIVATE ISSUERSEC 6-K
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list